Sintx Technologies granted sixth U.S. patent in last year

SINTX Technologies announced that it has been granted its sixth United States patent in the last year. All of these United States patents are related to the antipathogenic properties of silicon nitride. The six United States patents granted to SINTX are: 11,591,217; Antipathogenic Devices and Methods Thereof; 11,672,252; Antifungal Composites and Methods Thereof; 11,738,122; Antibacterial Biomedical Implants and Associated Materials, Apparatus, and Methods; 11,844,344; Systems and Methods for Rapid Inactivation of SARS-COV-2 by Silicon Nitride and Aluminum Nitride; 11,850,214; Antiviral Compositions and Devices and Methods of Use Thereof; 11,857,001; Antipathogenic Face Mask. The significance of the six mentioned patents lies in their innovative approaches towards utilizing silicon nitride in a wide range of antipathogenic solutions. The surface antipathogenic properties of silicon nitride have been published extensively in the peer literature by SINTX as well as by outside investigators. The Company announced it has also received three foreign patents on its proprietary technologies in 2023. SINTX has forty-three patent applications that are currently pending around the world including in the United States, Asia, Europe, and Brazil.